Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial
Bert H. O’Neil, Monica M. Bertagnolli, Daniel Mulkerin, Scott Berry, Eileen M. O’Reilly, Charles D. Blanke, Robert J. Mayer, Deborah Schrag, Claire Greene, Jeffrey A. Meyerhardt, James N. Atkins, Peter Watson, Blasé N. Polite, Al B. Benson, Howard S. Höchster, Donna Niedzwiecki, Richard L. Schilsky, Alan P. Venook, Heinz‐Josef Lenz, Federico Innocenti, Briant Fruth, Anthony B. El-Khoueiry, Richard M. Goldberg
Abstract
Combining biologic monoclonal antibodies with chemotherapeutic cytotoxic drugs provides clinical benefit to patients with advanced or metastatic colorectal cancer, but the optimal choice of the initial biologic therapy in previously untreated patients is unknown.
Topics & Concepts
CetuximabBevacizumabKRASMedicineOncologyColorectal cancerInternal medicineChemotherapyRandomized controlled trialClinical trialOverall survivalOxaliplatinCancerColorectal Cancer Treatments and StudiesGastric Cancer Management and OutcomesColorectal and Anal Carcinomas